Cargando…

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine‐resistant and cisplatin‐resistant BCs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshino, Hirofumi, Yokoyama, Seiya, Tamai, Motoki, Okamura, Shunsuke, Iizasa, Sayaka, Sakaguchi, Takashi, Osako, Yoichi, Inoguchi, Satoru, Matsushita, Ryosuke, Yamada, Yasutoshi, Nakagawa, Masayuki, Tatarano, Shuichi, Tanimoto, Akihide, Enokida, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240337/ https://www.ncbi.nlm.nih.gov/pubmed/37079001 http://dx.doi.org/10.1002/2211-5463.13616

Ejemplares similares

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
por: Tamai, Motoki, et al.
Publicado: (2022)

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients
por: Tatarano, Shuichi, et al.
Publicado: (2022)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
por: Mitsuke, Akihiko, et al.
Publicado: (2023)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer
por: CHIYOMARU, TAKESHI, et al.
Publicado: (2014)

Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness
por: Matsushita, Ryosuke, et al.
Publicado: (2016)

Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report
por: Yamada, Yasutoshi, et al.
Publicado: (2019)

The role of microRNAs in bladder cancer
por: Enokida, Hideki, et al.
Publicado: (2016)

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer
por: Matsushita, R, et al.
Publicado: (2015)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer
por: Yonemori, Masaya, et al.
Publicado: (2016)

Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Genome Editing Using Cas9 Ribonucleoprotein Is Effective for Introducing PDGFRA Variant in Cultured Human Glioblastoma Cell Lines
por: Hamada, Taiji, et al.
Publicado: (2022)

Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma
por: Hidaka, Hideo, et al.
Publicado: (2012)

Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma
por: YAMASAKI, TAKESHI, et al.
Publicado: (2012)

MALAT1 functions as a transcriptional promoter of MALAT1::GLI1 fusion for truncated GLI1 protein expression in cancer
por: Hamada, Taiji, et al.
Publicado: (2023)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors
por: Hamada, Taiji, et al.
Publicado: (2022)

Transcriptome analysis reveals key roles of AtLBR-2 in LPS-induced defense responses in plants
por: Iizasa, Sayaka, et al.
Publicado: (2017)

Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel
por: HIGA, Nayuta, et al.
Publicado: (2022)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
por: Yoshino, Takayuki, et al.
Publicado: (2015)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

Comprehensive validation of liquid-based cytology specimens for next-generation sequencing in cancer genome analysis
por: Akahane, Toshiaki, et al.
Publicado: (2019)

Protective Effects of Peroxiredoxin 4 (PRDX4) on Cholestatic Liver Injury
por: Zhang, Jing, et al.
Publicado: (2018)

Favorable prognostic impact of phosphatase and tensin homolog alterations in wild-type isocitrate dehydrogenase and telomerase reverse transcriptase promoter glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2023)

Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer
por: Miyamoto, K, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1lalvjo4putpfu2omd7bi6i6ed